Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. SBUX

Go back to Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share

Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress

December 17, 2015 7:00 AM EST

OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), today reports its financial results for the third quarter ended 31 October 2015.

Mr Glyn Edwards, Chief Executive Officer of Summit commented: We have recently announced positive clinical trial results for both our lead programmes in DMD and CDI, enabling us to advance these promising candidates to... More